Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA grants priority review for Gilead HIV drug
If the sNDA is approved, Truvada would be the first agent indicated for uninfected individuals to reduce the risk of acquiring HIV, the company said. The sNDA is
If the sNDA is approved, Truvada would be the first agent indicated for uninfected individuals to reduce the risk of acquiring HIV, the company said. The sNDA is
As of the expiration of the offer, 77,532,611 shares of common stock of Inhibitex were validly tendered and not withdrawn in the tender offer, the company said. Approximately
The upgraded version of the DNA sequencing system is referred to as C2. The PacBio RS reveals new biological insights by incorporating novel, single molecule sequencing techniques, advanced
The communications technology solution platform will bring together existing but isolated communications and healthcare IT infrastructure investments, the company said. The platform will leverage existing hospital and clinical
The plant, which is a joint venture between the SA government, through Pelchem, and Lonza, will be established near Pelindaba in Gauteng, the Times Live said. Ketlaphela, once
Recombinant and microbial P450 and glycosylating technology have been developed for accessing metabolites at mg to 100s grams scale, the company said. These enzymes, which resemble human systems,
As per the agreement, Tris will use its proprietary technology and will develop up to six new drug applications (NDAs), on behalf of Vernalis. Tris will undertake and
Uceris is a locally acting corticosteroid that utilizes proprietary MMX multi-matrix system technology to enable controlled release and distribution of budesonide throughout the length of the colon. The
The primary objective of the study is to evaluate the safety and tolerability of SGX201 and assess the preliminary efficacy of SGX201 for prevention of symptoms of acute
Tony Sedgwick has joined the company in September 2011 and has extensive experience from European life science companies including more than fifteen years at Roche. Prior to joining